Study:
The Use of Enoxaparin Compared to Unfractionated Heparin for Short Term Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing TEE Guided Cardioversion: Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Randomized Multicenter Study
Rationale:
n/a
Purpose:
SPECIFIC AIM: To test the safety and feasibility of using low molecular weight heparin
(LMWH, enoxaparin sodium; Lovenox, Sanofi-Aventis) in lieu of unfractionated heparin (UFH) as
antithrombotic therapy for patients in atrial fibrillation undergoing transesophageal
echocardiography (TEE) guided chemical or electrical cardioversion to sinus rhythm.
HYPOTHESIS: Early cardioversion from atrial fibrillation can be safely performed using a
short-term anticoagulation strategy of low molecular weight heparin (Lovenox, Sanofi-Aventis)
compared to unfractionated heparin, accompanied by a TEE examination prior to cardioversion.
The use of LMWH with TEE will result in a safe, cost-effective, and possible efficacious
approach to cardioversion of atrial fibrillation compared to UFH with TEE.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Atrial Fibrillation |
Drug: Enoxaparin |
Phase 4 |
Verified by
The Cleveland Clinic
May, 2005
Sponsored by: The Cleveland Clinic
Information provided by: The Cleveland Clinic
ClinicalTrials.gov identifier: NCT00289042
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Safety/Efficacy Study
Cleveland Clinic
Cleveland, Ohio 44195
United States
Allan L. Klein, MD., Principal Investigator